We would love to hear your thoughts about our site and services, please take our survey here.
Wigwarmer , you posted. This morning “ Some more perspective around the trial update would have been welcome - such as an expert opinion on the relevance of the 23 DTH responses”
Well we have one of the UK’s top experts giving his opinion on it which I have just posted.
All this talk of whether DTH is significant or not is pointless unless you are a professional in that field.
If you guys can’t work it out then why not take it from someone who is at the very top of their profession.
Taken straight from the last news release:
Prof Christian Ottensmeier, Chief Investigator, University of Liverpool commented: "The strong DTH responses in all patients and the early clinical results, particularly in the patient with advanced SCCHN, suggests that this therapeutic cancer vaccine could have significant potential. Further studies with Modi-1 monotherapy and in combination with CPIs should tell us in which settings it will have maximum benefit to patients."
Well if we can’t work it out, then listen to the people who do know !
Honorary Prof Rod Dawson, Managing Director of the University of Cape Town Lung Institute, commented:
"We are delighted to report the positive immune response data from the COVIDTY trial. 66 participants were immunised with SCOV1, targeting the original A lineage of SARS-CoV-2 and/or SCOV2, targeting the Beta variant of concern. The results from the trial were highly encouraging, inducing neutralising antibody and T cell responses with no safety concerns." '
M&A. Jean-Michel was Vice President for North America Oncology at Eli Lilly, with responsibility for commercialisation of the company's oncology portfolio . Preceding this US-based position, he was Vice President and Managing Director of the Eli Lilly's European Northern Hub, where he was Chair of the Eli Lilly UK Board and a member of Lilly European Executive Committee. Prior to this Jean-Michel served as VP and Chief Marketing Officer at GE Healthcare's Global Headquarters.
Following his retirement from Eli Lilly in 2018, Jean-Michel has served on the board of Kymab until their acquisition by Sanofi. He was also a member of the Immunocore board prior to the company's Nasdaq listing.